Purple Biotech reports preclinical data for IM1240 cancer treatment Apr 27, 2026 07:03AM
Purple Biotech Ltd. (PPBT) PT Lowered to $30 at H.C. Wainwright Mar 16, 2026 06:49AM
Purple Biotech Ltd. (PPBT) enters $2.3M ATM Sep 19, 2025 04:38PM
Purple Biotech Ltd. (PPBT) PT Raised to $34 at H.C. Wainwright May 30, 2025 06:41AM
Purple Biotech Ltd. (PPBT) Appoints Shai Lankry as CFO May 12, 2025 07:31AM


Apr 28, 2025 08:28AM Purple Biotech Ltd. (PPBT) Reports Positive NT219 Data
Sep 19, 2024 06:40AM Purple Biotech Ltd. (PPBT) PT Raised to $33 at H.C. Wainwright
Aug 19, 2024 06:40AM Purple Biotech Ltd. (PPBT) PT Lowered to $8 at H.C. Wainwright
Jul 25, 2024 07:35AM Purple Biotech Ltd. (PPBT) Receives Extension to Regain Compliance with the Nasdaq’s Minimum Bid Price Rule
Jul 12, 2024 08:19AM H.C. Wainwright Reiterates Buy Rating on Purple Biotech Ltd. (PPBT)
Jun 27, 2024 07:46AM Purple Biotech (PPBT) Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit